EPOCIM in benign prostatic hyperplasia.
Phase 3
Suspended
- Conditions
- Benign prostatic hyperplasia
- Registration Number
- RPCEC00000092
- Lead Sponsor
- Center of Molecular Immunology(CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Male
- Target Recruitment
- 306
Inclusion Criteria
1.Patients who fulfill the diagnostic criteria.
2.Patients older than 18 years.
3.Patients give their informed consent to participate in writing.
Exclusion Criteria
1.Uncontrolled hypertension.
2.Patients with known risk or a history of arterial or venous thromboembolic disease.
3.Severe cardiovascular disease: unstable angina, heart failure, aortic stenosis.
4.Severe vascular brain disease.
5.Known infectious diseases such as HIV/AIDS,Hepatitis B and C.
6.Patients with known hypersensitivity to products derived from cells above or hypersensitivity to human albumin.
7.Hematologic Diseases:Sicklemia,Myelodysplastic syndromes,Disorders of coagulation. 8.Surgical approach to patients with benign prostatic hyperplasia by transurethral.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Transfusion requirements (yes/no). Measuring time: three days after surgery
- Secondary Outcome Measures
Name Time Method